Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement by 葵花药业集团股份有限公司 detailing the convening of its 2025 annual general meeting, attendance statistics, each resolution proposed, and the precise voting results (number of shares for, against, abstained). It contains full disclosure of shareholder voting outcomes. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 Chinese
关于注销全资子公司的进展公告
Regulatory Filings Classification · 75% confidence The document is a corporate announcement updating on the deregistration (注销) of a wholly-owned subsidiary, with no financial statements or voting results, not a management change, financing update, or securities transaction. It is a miscellaneous regulatory update, so it falls under Regulatory Filings (RNS).
2026-05-19 Chinese
关于参加黑龙江辖区上市公司2026年投资者网上集体接待日活动的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in an investor online collective reception day event. It mentions the date and time of the event and that company directors and executives will communicate with investors about various topics including 2025 annual performance, governance, strategy, financing plans, and sustainability. The document is short (520 characters) and does not contain any financial statements or detailed financial data. It is not a report itself but an announcement of an event for investor communication. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, albeit in an event format rather than a document. Confidence is high due to clear description of investor communication event.
2026-05-08 Chinese
关于独立董事独立性自查情况的专项报告
Governance Information Classification · 82% confidence The document is a special report by the board evaluating the independence of the company’s independent directors, referencing listing rule requirements and self-regulatory guidelines. It is not announcing a board change, vote result, financial results, nor is it a simple report publication notice. Instead, it details the company’s governance practices around director independence, fitting the Governance Information category.
2026-04-26 Chinese
高级管理人员2026年度薪酬方案
Remuneration Information Classification · 95% confidence The document is a detailed annual compensation plan for senior management of 葵花药业集团股份有限公司 for the 2026 fiscal year. It outlines salary structure, performance pay, incentive schemes, payment policies, and related rules. This matches the definition of Remuneration Information (DEF 14A), which covers reports detailing executive/director compensation.
2026-04-26 Chinese
独立董事述职报告-张盈
Governance Information Classification · 85% confidence The document is an independent director’s annual performance report (“独立董事述职报告”), detailing governance activities, committee attendances, and board oversight functions. It is not announcing voting results, director changes, or financial results, but describes corporate governance practices and the director’s duties. This aligns with the Governance Information category.
2026-04-26 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.